Argent Capital Management LLC Has $16.52 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Argent Capital Management reduced its Thermo Fisher stake by 35.8% in the first quarter, selling 18,757 shares and retaining 33,602 shares valued at approximately $16.52 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher beat second-quarter expectations: adjusted EPS came in at $6.03 versus $5.71 expected, while revenue rose 10.5% year over year to $11.99 billion. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $617.14; Barclays and Morgan Stanley recently raised their targets to $650. Shares opened at $575.20, while COO Gianluca Pettiti sold 400 shares under a pre-arranged trading plan.

Argent Capital Management LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,602 shares of the medical research company's stock after selling 18,757 shares during the quarter. Argent Capital Management LLC's holdings in Thermo Fisher Scientific were worth $16,517,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Wealth Managment LLC ID lifted its stake in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after buying an additional 22 shares during the last quarter. High Note Wealth LLC lifted its position in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $28,000. JPL Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $28,000. Finally, MBM Wealth Consultants LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $29,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Ratings Changes

TMO has been the subject of a number of research analyst reports. Barclays upped their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Piper Sandler boosted their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a report on Monday. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $617.14.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares of the company's stock, valued at $13,927,815. The trade was a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q2 earnings beat expectations: Thermo Fisher reported adjusted EPS of $6.03 versus the $5.71 analyst consensus, while revenue increased 10.5% year over year to $11.99 billion, above the $11.71 billion forecast. Management cited broad-based momentum across pharmaceutical, biotechnology, industrial and diagnostics markets. The Top 5 Analyst Questions From Thermo Fisher’s Q2 Earnings Call
• Positive Sentiment: Growth initiatives are gaining attention: Expansion in bioproduction, high-end instruments, AI-powered software and clinical-data capabilities could support long-term growth as pharmaceutical and biotech activity improves. Recent regulatory clearances across the diagnostics portfolio also strengthen the company’s product offering. How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends
• Positive Sentiment: Analyst estimates and sentiment remain supportive: Erste Group raised its FY2026 EPS estimate to $25.12 from $24.85 and its FY2027 estimate to $27.43 from $27.19. Brokerages collectively maintain a “Moderate Buy” recommendation, and one analysis estimates TMO is approximately 2% undervalued following the earnings beat. Thermo Fisher Receives Consensus Recommendation of Moderate Buy
• Neutral Sentiment: Strong recent performance raises the bar: TMO’s reported 30-day share-price return of 15.04% and 90-day return of 22.92% reflect optimism already priced into the stock, increasing the importance of further earnings delivery.
• Negative Sentiment: Competition and execution remain risks: Thermo Fisher’s AI, bioproduction and clinical-data investments offer growth opportunities, but intensifying competition means delays or weaker-than-expected adoption could pressure future results and the premium valuation.

Thermo Fisher Scientific Stock Down 0.3%

Thermo Fisher Scientific stock opened at $575.20 on Friday. The company has a 50 day moving average of $506.51 and a 200-day moving average of $512.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The stock has a market capitalization of $213.75 billion, a PE ratio of 30.94, a price-to-earnings-growth ratio of 2.35 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.